Radcliffe Capital Management’s GreenLight Biosciences Holdings, PBC Common Stock GRNA Stock Holding History

Radcliffe Capital Management’s Portfolio GRNA Stock Details GRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-89,754	Closed	-$890K	–	1269
2021 Q4	$890K	Hold	89,754	–	–	0.02%	878
2021 Q3	$888K	Hold	89,754	–	–	0.03%	741
2021 Q2	$880K	Buy	+89,754	New	+$875K	0.03%	762

Other funds holding GRNA

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

VK Services Menlo Park, California $543K AUM 174.84% 1-Year Est. Return

CGC

Continental Grain Company New York $366M AUM 0.18% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

TCM

Tao Capital Management San Francisco, California $119M AUM 87.46% 1-Year Est. Return

BOTOTLSJU

Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

OCMH

Oxbow Capital Management (HK) Hong Kong $371M AUM 383.45% 1-Year Est. Return

Radcliffe Capital Management's GRNA Position: Q1 2022 in Review

Radcliffe Capital Management sold out of GreenLight Biosciences Holdings, PBC Common Stock (GRNA) in Q1 2022, closing a stake of 89,754 shares — an estimated $890K sold.

Radcliffe Capital Management first reported a position in GRNA in Q2 2021 and held it in 3 quarters. The position peaked at $890K in Q4 2021. 39 funds tracked by Wall St. Rank hold GRNA as of Q1 2022.

Radcliffe Capital Management reported no remaining GreenLight Biosciences Holdings, PBC Common Stock position as of Q1 2022 after selling out during the quarter.
Radcliffe Capital Management sold 89,754 GreenLight Biosciences Holdings, PBC Common Stock shares in Q1 2022, an estimated $890K.
Radcliffe Capital Management first reported a position in GreenLight Biosciences Holdings, PBC Common Stock in Q2 2021 and held it in 3 quarters.
Radcliffe Capital Management's GreenLight Biosciences Holdings, PBC Common Stock position peaked at $890K in Q4 2021.
39 funds tracked by Wall St. Rank held GreenLight Biosciences Holdings, PBC Common Stock as of Q1 2022.

Based on Radcliffe Capital Management's 13F filing for Q1 2022, filed 16 May 2022.